Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This...
fibrosis
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the...
Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the...
Nerandomilast (BI 1015550) is an investigational oral drug that selectively inhibits phosphodiesterase 4B, exhibiting antifibrotic and immune-modulating effects. In previous...
Nerandomilast met its primary end point of absolute change from baseline in forced vital capacity (FVC) vs placebo in the...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical...
